Old drug, new hope: could filgotinib tame rare immune diseases?

NCT ID NCT06285539

Recruiting now Disease control Sponsor: UMC Utrecht Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether filgotinib, a drug already used for arthritis, can help people with three rare immune diseases: Behçet's disease, myositis, and IgG4-related disease. The goal is to see if it can control disease activity and reduce the need for long-term steroids. Sixty adults with active disease will receive the drug and be monitored for changes in symptoms and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Filgotinib (a JAK inhibitor drug)
What this could lead to: If successful, this could offer a new, more targeted treatment option for three rare inflammatory diseases, potentially reducing reliance on high-dose steroids.
What could go wrong: This is a small, early-phase trial (60 participants) testing a drug already approved for other conditions. It may not show enough benefit or could have side effects like infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEHCET'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy Behcet disease idiopathic inflammatory myopathy Immunoglobulin G4-Related Disease immunoglobulin G4-related sclerosing disease myositis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BEHCET'S DISEASE IDIOPATHIC INFLAMMATORY MYOPATHIES IGG4-RELATED DISEASE

Contacts and locations

Locations

Amsterdam UMC
RECRUITING

Amsterdam, Netherlands
Erasmus MC
RECRUITING

Rotterdam, Netherlands
Hagaziekenhuis
RECRUITING

The Hague, Netherlands
Radboud university medical center
RECRUITING

Nijmegen, Netherlands
University Medical Center
RECRUITING

Utrecht, Netherlands
Zuyderland Medical Center
RECRUITING

Heerlen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.